Caylib Durand

Caylib Durand

UNVERIFIED PROFILE

Are you Caylib Durand?   Register this Author

Register author
Caylib Durand

Caylib Durand

Publications by authors named "Caylib Durand"

Are you Caylib Durand?   Register this Author

7Publications

37Reads

-Profile Views

Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: A systematic review.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

From the Department of Medicine and Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta; Arthritis Research Canada; Centre for Health Evaluation and Outcome Sciences, Providence Health Care, St Paul's Hospital, Vancouver, British Columbia. The work was supported in part by a Canadian Initiative for Outcomes in Rheumatology Care (CIORA) grant. Dr. Hazlewood is supported by a Canadian Institute of Health Research (CIHR) New Investigator Salary Award and The Arthritis Society Young Investigator Salary Award. Dr. Marshall is supported by a CIHR Canada Research Chair in Health Services and Systems Resea. Address correspondence to Dr. Glen Hazlewood, 3330 Hospital Dr NW, Calgary, Alberta, Canada, T2N 4N1 Tel: (403) 220-5903, Fax: (403) 210-7367 Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181165DOI Listing
April 2019

Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts.

Biol Blood Marrow Transplant 2016 May 9;22(5):815-24. Epub 2016 Jan 9.

Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Health Services, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.01.002DOI Listing
May 2016

The use of popular fiction to present a professional scientific career to high school students.

J Microbiol Biol Educ 2010 20;11(2):166-7. Epub 2010 Dec 20.

Life Sciences Institute Graduate Student Association (LSI-GSA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/jmbe.v11i2.194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577188PMC
May 2013

Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.

Autoimmunity 2013 Feb;46(1):62-73

Department of Microbiology and Immunology, Infection, Inflammation, and Immunity (I3) Research Group, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08916934.2012.732130DOI Listing
February 2013

Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.

J Immunol 2009 Nov;183(9):5673-84

Department of Microbiology and Immunology, Infection, Inflammation, and Immunity (I(3)) and CELL Research Groups, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.0900432DOI Listing
November 2009

The Rap GTPases mediate CXCL13- and sphingosine1-phosphate-induced chemotaxis, adhesion, and Pyk2 tyrosine phosphorylation in B lymphocytes.

Eur J Immunol 2006 Aug;36(8):2235-49

Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.200535004DOI Listing
August 2006